Last reviewed · How we verify
Sanchitongshu
Sanchitongshu is a Small molecule drug developed by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine. It is currently in Phase 1 development. Also known as: Radix/Rhizoma Notoginseng extract.
Sanchitongshu is being studied in a clinical trial as a potential treatment to prevent ischemic stroke, in combination with antiplatelet drugs such as Aspirin and Clopidogrel. The trial, NCT04142151, is a double-blind, placebo-controlled study conducted by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Sanchitongshu |
|---|---|
| Also known as | Radix/Rhizoma Notoginseng extract |
| Sponsor | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Double Randomized and Placebo Controlled Trail of Sanchitongshu Combined Antiplatelet Drug to Prevent Ischemic Stroke (NA)
- Sanchitongtshu Plus Asprine for Minor Ischemic Stroke or Transient Ischemic Attack: A Randomized Double-blind Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sanchitongshu CI brief — competitive landscape report
- Sanchitongshu updates RSS · CI watch RSS
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine portfolio CI
Frequently asked questions about Sanchitongshu
What is Sanchitongshu?
Who makes Sanchitongshu?
Is Sanchitongshu also known as anything else?
What development phase is Sanchitongshu in?
Related
- Manufacturer: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Radix/Rhizoma Notoginseng extract
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing